Adenosine-rich extract of Ganoderma lucidum: A safe and effective lipid-lowering substance

He Li; Yawei Du; Hanrui Ji; Yanan Yang; Changchang Xu; Qiaodan Li; Longkai Ran; Chongming Wu; Qile Zhou; Shengxian Wu

doi:10.1016/j.isci.2022.105214

Adenosine-rich extract of Ganoderma lucidum: A safe and effective lipid-lowering substance

iScience. 2022 Sep 26;25(11):105214. doi: 10.1016/j.isci.2022.105214. eCollection 2022 Nov 18.

Authors

He Li^{1

2}, Yawei Du¹, Hanrui Ji¹, Yanan Yang³, Changchang Xu¹, Qiaodan Li¹, Longkai Ran¹, Chongming Wu⁴, Qile Zhou⁵, Shengxian Wu¹

Affiliations

¹ Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
² Shandong University of Traditional Chinese Medicine, Shandong 250355, China.
³ Pharmacology and Toxicology Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.
⁴ School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
⁵ Beijing Institute of Nutritional Resources, Beijing Academy of Science and Technology, Beijing 100069, China.

Abstract

Ganoderma lucidum is a traditional Chinese medicine with a variety of active compounds and possesses adequate lipid-lowering and anti-atherosclerotic effects. However, its main active components and potential mechanisms still remain unclear. Here, we evaluated the anti-hyperlipidemic effect of the adenosine extract from Ganoderma lucidum (AEGL) in high-fat-diet (HFD)-induced hyperlipidemic ApoE^-/- mice and explored the underlying biological mechanism by multi-omics analysis. Treatment with AEGL for 8 weeks significantly decreased the serum levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-c) by 45.59%, 41.22%, and 39.02%, respectively, as well as reduced liver TC and TG by 44.15% and 76.23%, compared with the HFD-only group. We also observed significant amelioration of hepatic steatosis without liver and kidney damage after AEGL treatment. Regulating the expression and acetylation/crotonylation of proteins involved in the PPAR signaling pathway may be one of the potential mechanisms involved in the observed lipid-lowering effects of AEGL.

Keywords: Alternative medicine; lipid; omics; physiology.